Добро пожаловать
Нажатие «Авторизоваться» означает, что вы соглашаетесь с Условия использования и политика конфиденциальности Cointime.
Зарегистрировать аккаунт
Аккаунт уже существует?
Нажатие «page.Sign up» означает, что вы соглашаетесь с <a class="underline" href="#term-of-service">Условия использования</a> и a class="underline" href="#privacy-policy">политика конфиденциальности</a> Cointime.
Войдите, используя email
Зарегистрируйтесь с помощью email
твой почтовый ящик
Проверь свои входящие
Нажмите на ссылку в , чтобы войти.
Нажмите на ссылку в , чтобы зарегистрироваться.
Cimeio Therapeutics
company
About
Cimeio Therapeutics develops curative treatments for genetic diseases, hematologic malignancies, and severe autoimmune disorders.
- 11 - 50
Details
- Last Funding Type
- Series A
- Last Funding Money Raised
- $50M
- Industries
- Biopharma,Biotechnology,Health Care,Medical
- Founded date
- Jan 1, 2020
- Number Of Employee
- 11 - 50
- Operating Status
- Active
Funding Rounds
Number of Funding Rounds
Total Funding Amount
1
$50M
Cimeio Therapeutics has raised a total of
$50M
in funding over 2 rounds. Their latest funding was raised on
Apr 13, 2022 from a Series A round.
| Announced Date | Round | Money Raised | Number of Investors | Lead Investors | Post Valuation | |
|---|---|---|---|---|---|---|
| Apr 13, 2022 | Series A | $50M | 1 |
Versant Ventures
|
— | Detail |
Investments
Number of Investments
Number of Lead Investments
2
0
Cimeio Therapeutics has made 2 investments. Their most recent investment was on
Oct 12, 2021, when FrankieOne raised $20M.
|
Date
Company Name
|
Round | Money Raised | Industry | Lead Investor |
|---|---|---|---|---|
|
Oct 12, 2021
FrankieOne
|
Series A | $20M | Developer APIs | — |
|
Jul 28, 2021
Quansa
|
Seed | $3.58M | Employee Benefits | — |
Investors
Number of Lead Investors
Number of Investors
1
1
Cimeio Therapeutics is funded by 1 investors.
Versant Ventures
are the most recent investors.
| Investor Name | Lead Investor | Funding Round |
|---|---|---|
|
Versant Ventures
|
Yes | Series A |
Share
Twitter
LinkedIn
Line
Facebook
Telegram
Email
Page Link
